{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:50:08Z","timestamp":1788457808925,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04539-4","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:23:45Z","timestamp":1761294225000},"page":"4607-4623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT\/Bcl2 pathway in breast cancer"],"prefix":"10.1007","volume":"399","author":[{"given":"Hongxia","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"1","key":"4539_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.63623\/9k14tf70","volume":"1","author":"Ren J","year":"2024","unstructured":"Ren J (2024) Advances in combination therapy for gastric cancer: integrating targeted agents and immunotherapy.\u00a0Clin Pharmacol Ther 1(1):1\u201315.\u00a0https:\/\/doi.org\/10.63623\/9k14tf70","journal-title":"Advances in Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"4539_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.62382\/jcbt.v1i1.13","volume":"1","author":"M Ashrafizadeh","year":"2024","unstructured":"Ashrafizadeh M (2024) Cell death mechanisms in human cancers: molecular pathways, therapy resistance and therapeutic perspective. Journal of Cancer Biomoleculars and Therapeutics 1(1):17\u201340. https:\/\/doi.org\/10.62382\/jcbt.v1i1.13","journal-title":"Journal of Cancer Biomoleculars and Therapeutics"},{"key":"4539_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S et al (2020) Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol 84:106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4539_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4539_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658552","volume":"11","author":"J Cao","year":"2021","unstructured":"Cao J, Zhang M, Wang B, Zhang L, Fang M, Zhou F (2021) Chemoresistance and metastasis in breast cancer molecular mechanisms and novel clinical strategies. Front Oncol 11:658552. https:\/\/doi.org\/10.3389\/fonc.2021.658552","journal-title":"Front Oncol"},{"key":"4539_CR6","doi-asserted-by":"publisher","unstructured":"Chen J, Xu J, Yang J, Zhan Y, Li S, Jia L, et al (2023a) \u03b1\u2011hederin overcomes hypoxia\u2011mediated drug resistance in colorectal cancer by inhibiting the AKT\/Bcl2 pathway. Int J Oncol 62(3):33. https:\/\/doi.org\/10.3892\/ijo.2023.5481","DOI":"10.3892\/ijo.2023.5481"},{"issue":"2","key":"4539_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2478\/acph-2023-0016","volume":"73","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yin L, Hao M, Xu W, Gao J, Sun Y et al (2023b) Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells. Acta Pharm 73(2):211\u2013225. https:\/\/doi.org\/10.2478\/acph-2023-0016","journal-title":"Acta Pharm"},{"issue":"4","key":"4539_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.38212\/2224-6614.3377","volume":"29","author":"CM Chern","year":"2021","unstructured":"Chern CM, Lu CK, Liou KT, Wang YH, Tsai KC, Chang CL et al (2021) Medicarpin isolated from Radix Hedysari ameliorates brain injury in a murine model of cerebral ischemia. J Food Drug Anal 29(4):581\u2013605. https:\/\/doi.org\/10.38212\/2224-6614.3377","journal-title":"J Food Drug Anal"},{"issue":"4","key":"4539_CR9","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.7150\/ijbs.83774","volume":"20","author":"W Du","year":"2024","unstructured":"Du W, Tu S, Zhang W, Zhang Y, Liu W, Xiong K et al (2024) UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT. Int J Biol Sci 20(4):1389\u20131409. https:\/\/doi.org\/10.7150\/ijbs.83774","journal-title":"Int J Biol Sci"},{"issue":"13","key":"4539_CR10","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.phymed.2015.09.005","volume":"22","author":"G Gatouillat","year":"2015","unstructured":"Gatouillat G, Magid AA, Bertin E, El btaouri H, Morjani H, Lavaud C et al (2015) Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells. Phytomedicine 22(13):1186\u20131194. https:\/\/doi.org\/10.1016\/j.phymed.2015.09.005","journal-title":"Phytomedicine"},{"key":"4539_CR11","doi-asserted-by":"publisher","unstructured":"Gentilin E (2023) New advancements in cisplatin-based treatments. Int J Mol Sci 24(6):5920. https:\/\/doi.org\/10.3390\/ijms24065920","DOI":"10.3390\/ijms24065920"},{"key":"4539_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S (2019) Cisplatin: the first metal based anticancer drug. Bioorg Chem 88:102925. https:\/\/doi.org\/10.1016\/j.bioorg.2019.102925","journal-title":"Bioorg Chem"},{"issue":"1","key":"4539_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"issue":"1","key":"4539_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1186\/s12885-017-3695-5","volume":"17","author":"K Gohr","year":"2017","unstructured":"Gohr K, Hamacher A, Engelke LH, Kassack MU (2017) Inhibition of PI3K\/Akt\/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer 17(1):711. https:\/\/doi.org\/10.1186\/s12885-017-3695-5","journal-title":"BMC Cancer"},{"issue":"1","key":"4539_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ogc.2021.11.010","volume":"49","author":"VF Grabinski","year":"2022","unstructured":"Grabinski VF, Brawley OW (2022) Disparities in breast cancer. Obstet Gynecol Clin North Am 49(1):149\u2013165. https:\/\/doi.org\/10.1016\/j.ogc.2021.11.010","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"4","key":"4539_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH et al (2020) Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(4):452\u2013478. https:\/\/doi.org\/10.6004\/jnccn.2020.0016","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"4539_CR17","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1038\/s12276-022-00822-z","volume":"54","author":"JY Hahm","year":"2022","unstructured":"Hahm JY, Park J, Jang ES, Chi SW (2022) 8-oxoguanine: from oxidative damage to epigenetic and epitranscriptional modification. Exp Mol Med 54(10):1626\u20131642. https:\/\/doi.org\/10.1038\/s12276-022-00822-z","journal-title":"Exp Mol Med"},{"key":"4539_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113774","volume":"155","author":"M Hashemi","year":"2022","unstructured":"Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M et al (2022) EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions. Biomed Pharmacother 155:113774. https:\/\/doi.org\/10.1016\/j.biopha.2022.113774","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"4539_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"4539_CR20","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.18632\/aging.204673","volume":"15","author":"TY Hsieh","year":"2023","unstructured":"Hsieh TY, Sung WW, Chang YC, Yu CY, Lu LY, Dong C et al (2023) Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma. Aging (Albany N y) 15(8):3107\u20133119. https:\/\/doi.org\/10.18632\/aging.204673","journal-title":"Aging (Albany N y)"},{"issue":"1","key":"4539_CR21","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1038\/s41467-022-31645-1","volume":"13","author":"L Huang","year":"2022","unstructured":"Huang L, Zhang XO, Rozen EJ, Sun X, Sallis B, Verdejo-Torres O et al (2022) PRMT5 activates AKT via methylation to promote tumor metastasis. Nat Commun 13(1):3955. https:\/\/doi.org\/10.1038\/s41467-022-31645-1","journal-title":"Nat Commun"},{"issue":"5","key":"4539_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0303213","volume":"19","author":"JB Kang","year":"2024","unstructured":"Kang JB, Koh PO (2024) Retinoic acid alleviates the reduction of Akt and Bad phosphorylation and regulates Bcl-2 family protein interactions in animal models of ischemic stroke. PLoS ONE 19(5):e0303213. https:\/\/doi.org\/10.1371\/journal.pone.0303213","journal-title":"PLoS ONE"},{"key":"4539_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179617","author":"A Kawiak","year":"2022","unstructured":"Kawiak A (2022) Molecular research and treatment of breast cancer. Int J Mol Sci 23(17): 9617.\u00a0https:\/\/doi.org\/10.3390\/ijms23179617","journal-title":"Int J Mol Sci"},{"key":"4539_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215474","author":"J Kim","year":"2021","unstructured":"Kim J, Jang G, Sim SH, Park IH, Kim K, Park C (2021) SMARCA4 depletion induces cisplatin resistance by activating YAP1-mediated epithelial-to-mesenchymal transition in triple-negative breast cancer. Cancers (Basel) 13(21):5474. https:\/\/doi.org\/10.3390\/cancers13215474","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4539_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41419-022-04568-4","volume":"13","author":"JY Kim","year":"2022","unstructured":"Kim JY, Bahar E, Lee JY, Chang S, Kim SH, Park EY et al (2022) ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma. Cell Death Dis 13(3):239. https:\/\/doi.org\/10.1038\/s41419-022-04568-4","journal-title":"Cell Death Dis"},{"issue":"1","key":"4539_CR26","doi-asserted-by":"publisher","first-page":"18423","DOI":"10.1038\/s41598-022-21856-3","volume":"12","author":"S Kitayama","year":"2022","unstructured":"Kitayama S, Ikeda K, Sato W, Takeshita H, Kawakami S, Inoue S et al (2022) Testis-expressed gene 11 inhibits cisplatin-induced DNA damage and contributes to chemoresistance in testicular germ cell tumor. Sci Rep 12(1):18423. https:\/\/doi.org\/10.1038\/s41598-022-21856-3","journal-title":"Sci Rep"},{"key":"4539_CR27","doi-asserted-by":"publisher","unstructured":"Levone BR, Lenzken SC, Antonaci M, Maiser A, Rapp A, Conte F, et al (2021) FUS-dependent liquid-liquid phase separation is important for DNA repair initiation. J Cell Biol 220(5):e202008030.  https:\/\/doi.org\/10.1083\/jcb.202008030","DOI":"10.1083\/jcb.202008030"},{"issue":"6","key":"4539_CR28","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s12640-022-00610-7","volume":"40","author":"Y Li","year":"2022","unstructured":"Li Y, He X, Zhang J, Zhou Q, Liu X, Zhou G (2022) Medicarpin improves depressive-like behaviors in a chronic unpredictable mild stress-induced mouse model of depression by upregulating liver X receptor \u03b2 expression in the amygdala. Neurotox Res 40(6):1937\u20131947. https:\/\/doi.org\/10.1007\/s12640-022-00610-7","journal-title":"Neurotox Res"},{"key":"4539_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109498","volume":"120","author":"W Luo","year":"2019","unstructured":"Luo W, Ai L, Wang BF, Zhou Y (2019) High glucose inhibits myogenesis and induces insulin resistance by down-regulating AKT signaling. Biomed Pharmacother 120:109498. https:\/\/doi.org\/10.1016\/j.biopha.2019.109498","journal-title":"Biomed Pharmacother"},{"key":"4539_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106299","volume":"82","author":"MN Mansoori","year":"2020","unstructured":"Mansoori MN, Raghuvanshi A, Shukla P, Awasthi P, Trivedi R, Goel A et al (2020) Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Int Immunopharmacol 82:106299. https:\/\/doi.org\/10.1016\/j.intimp.2020.106299","journal-title":"Int Immunopharmacol"},{"key":"4539_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.662232","volume":"12","author":"F Martorana","year":"2021","unstructured":"Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR et al (2021) Akt inhibitors: new weapons in the fight against breast cancer? Front Pharmacol 12:662232. https:\/\/doi.org\/10.3389\/fphar.2021.662232","journal-title":"Front Pharmacol"},{"issue":"9","key":"4539_CR32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14656566.2020.1746273","volume":"21","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Nuzzolese I, Ponzone R (2020) Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother 21(9):1071\u20131082. https:\/\/doi.org\/10.1080\/14656566.2020.1746273","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"4539_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13046-018-0772-9","volume":"37","author":"HJ Park","year":"2018","unstructured":"Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH et al (2018) The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma. J Exp Clin Cancer Res 37(1):107. https:\/\/doi.org\/10.1186\/s13046-018-0772-9","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"4539_CR34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","volume":"99","author":"O Saatci","year":"2021","unstructured":"Saatci O, Huynh-Dam KT, Sahin O (2021) Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med (Berl) 99(12):1691\u20131710. https:\/\/doi.org\/10.1007\/s00109-021-02136-5","journal-title":"J Mol Med (Berl)"},{"issue":"24","key":"4539_CR35","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/0008-5472.Can-24-1846","volume":"84","author":"E Sementino","year":"2024","unstructured":"Sementino E, Hassan D, Bellacosa A, Testa JR (2024) AKT and the hallmarks of cancer. Cancer Res 84(24):4126\u20134139. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-1846","journal-title":"Cancer Res"},{"issue":"1","key":"4539_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2478\/acph-2024-0006","volume":"74","author":"Z Shen","year":"2024","unstructured":"Shen Z, Yin L, Chang M, Wang H, Hao M, Liang Y et al (2024a) Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis. Acta Pharm 74(1):149\u2013164. https:\/\/doi.org\/10.2478\/acph-2024-0006","journal-title":"Acta Pharm"},{"key":"4539_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103035","volume":"70","author":"M Shen","year":"2024","unstructured":"Shen M, Cao S, Long X, Xiao L, Yang L, Zhang P et al (2024b) DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT. Redox Biol 70:103035. https:\/\/doi.org\/10.1016\/j.redox.2024.103035","journal-title":"Redox Biol"},{"issue":"3","key":"4539_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/jjco\/hyz213","volume":"50","author":"T Shien","year":"2020","unstructured":"Shien T, Iwata H (2020) Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol 50(3):225\u2013229. https:\/\/doi.org\/10.1093\/jjco\/hyz213","journal-title":"Jpn J Clin Oncol"},{"key":"4539_CR39","doi-asserted-by":"publisher","unstructured":"Sun Y, Liu X, Tong H, Yin H, Li T, Zhu J, et al (2023) SIRT1 promotes cisplatin resistance in bladder cancer via Beclin1 deacetylation-mediated autophagy. Cancers (Basel) 16(1):125. https:\/\/doi.org\/10.3390\/cancers16010125","DOI":"10.3390\/cancers16010125"},{"key":"4539_CR40","doi-asserted-by":"publisher","unstructured":"Tian Y, Chen ZH, Wu P, Zhang D, Ma Y, Liu XF, et al (2023) MIR497HG-derived miR-195 and miR-497 mediate tamoxifen resistance via PI3K\/AKT signaling in breast cancer. Adv sci (Weinheim, Baden-Wurttemberg, Germany) 10(12):e2204819\u00a0https:\/\/doi.org\/10.1002\/advs.202204819","DOI":"10.1002\/advs.202204819"},{"issue":"1","key":"4539_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-022-00860-9","volume":"29","author":"PJ Tsai","year":"2022","unstructured":"Tsai PJ, Lai YH, Manne RK, Tsai YS, Sarbassov D, Lin HK (2022) Akt: a key transducer in cancer. J Biomed Sci 29(1):76. https:\/\/doi.org\/10.1186\/s12929-022-00860-9","journal-title":"J Biomed Sci"},{"issue":"22","key":"4539_CR42","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL et al (2023) Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 388(22):2058\u20132070. https:\/\/doi.org\/10.1056\/NEJMoa2214131","journal-title":"N Engl J Med"},{"key":"4539_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-0716-2433-3_7","volume":"2519","author":"KD Walsh","year":"2023","unstructured":"Walsh KD, Kato TA (2023) Alkaline comet assay to detect DNA damage. Methods Mol Biol 2519:65\u201372. https:\/\/doi.org\/10.1007\/978-1-0716-2433-3_7","journal-title":"Methods Mol Biol"},{"key":"4539_CR44","doi-asserted-by":"publisher","unstructured":"Wang H, Guo S, Kim SJ, Shao F, Ho JWK, Wong KU et al (2021) Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics 11(5):2442\u201359. https:\/\/doi.org\/10.7150\/thno.46460","DOI":"10.7150\/thno.46460"},{"issue":"2","key":"4539_CR45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11064-021-03449-0","volume":"47","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang R, Yan F, Jin Y, Liu X, Wang T (2022) Medicarpin protects cerebral microvascular endothelial cells against oxygen-glucose deprivation\/reoxygenation-induced injury via the PI3K\/Akt\/FoxO pathway: a study of network pharmacology analysis and experimental validation. Neurochem Res 47(2):347\u2013357. https:\/\/doi.org\/10.1007\/s11064-021-03449-0","journal-title":"Neurochem Res"},{"issue":"14","key":"4539_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18536","volume":"28","author":"J Wang","year":"2024","unstructured":"Wang J, Gu L, Shi Z, Xu Z, Zhai X, Zhou S et al (2024) 5-aminolevulinic acid photodynamic therapy protects against UVB-induced skin photoaging: a DNA-repairing mechanism involving the BER signalling pathway. J Cell Mol Med 28(14):e18536. https:\/\/doi.org\/10.1111\/jcmm.18536","journal-title":"J Cell Mol Med"},{"issue":"10","key":"4539_CR47","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/0008-5472.Can-22-2233","volume":"83","author":"R Xie","year":"2023","unstructured":"Xie R, Cheng L, Huang M, Huang L, Chen Z, Zhang Q et al (2023) NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res 83(10):1666\u20131683. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-2233","journal-title":"Cancer Res"},{"issue":"1","key":"4539_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7150\/ijbs.53795","volume":"17","author":"JC Xu","year":"2021","unstructured":"Xu JC, Chen TY, Liao LT, Chen T, Li QL, Xu JX et al (2021) Neto2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K\/AKT and ERK pathway. Int J Biol Sci 17(1):259\u2013270. https:\/\/doi.org\/10.7150\/ijbs.53795","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4539_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A et al (2023) Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer 22(1):105. https:\/\/doi.org\/10.1186\/s12943-023-01805-y","journal-title":"Mol Cancer"},{"key":"4539_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148735","volume":"927","author":"YF Yin","year":"2024","unstructured":"Yin YF, Jia QY, Yao HF, Zhu YH, Zheng JH, Duan ZH et al (2024) OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Gene 927:148735. https:\/\/doi.org\/10.1016\/j.gene.2024.148735","journal-title":"Gene"},{"issue":"5","key":"4539_CR51","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/cbdd.14309","volume":"102","author":"L Ying","year":"2023","unstructured":"Ying L, Hao M, Zhang Z, Guo R, Liang Y, Yu C et al (2023) Medicarpin suppresses proliferation and triggeres apoptosis by upregulation of BID, BAX, CASP3, CASP8, and CYCS in glioblastoma. Chem Biol Drug des 102(5):1097\u20131109. https:\/\/doi.org\/10.1111\/cbdd.14309","journal-title":"Chem Biol Drug des"},{"key":"4539_CR52","doi-asserted-by":"publisher","unstructured":"Yu T, Li Y, Gu X, Li Q (2020) Development of a hyaluronic acid-based nanocarrier incorporating doxorubicin and cisplatin as a pH-sensitive and CD44-targeted anti-breast cancer drug delivery system. Frontiers in Pharmacology 11:532457. https:\/\/doi.org\/10.3389\/fphar.2020.532457","DOI":"10.3389\/fphar.2020.532457"},{"key":"4539_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/bs.acr.2021.03.008","volume":"152","author":"J Zhang","year":"2021","unstructured":"Zhang J, Ye ZW, Tew KD, Townsend DM (2021a) Cisplatin chemotherapy and renal function. Adv Cancer Res 152:305\u2013327. https:\/\/doi.org\/10.1016\/bs.acr.2021.03.008","journal-title":"Adv Cancer Res"},{"issue":"8","key":"4539_CR54","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s10620-020-06579-7","volume":"66","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chen H, Song Y, Gu Q, Zhang L, Xie Q et al (2021b) Mir-325 promotes oxaliplatin-induced cytotoxicity against colorectal cancer through the HSPA12B\/PI3K\/AKT\/Bcl-2 pathway. Dig Dis Sci 66(8):2651\u20132660. https:\/\/doi.org\/10.1007\/s10620-020-06579-7","journal-title":"Dig Dis Sci"},{"issue":"1","key":"4539_CR55","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41598-024-51627-1","volume":"14","author":"M Zhang","year":"2024","unstructured":"Zhang M, Yuan J, Wang M, Zhang M, Chen H (2024) Chemotherapy is of prognostic significance to metaplastic breast cancer. Sci Rep 14(1):1210. https:\/\/doi.org\/10.1038\/s41598-024-51627-1","journal-title":"Sci Rep"},{"issue":"13","key":"4539_CR56","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.1111\/jcmm.15300","volume":"24","author":"M Zhao","year":"2020","unstructured":"Zhao M, Zhang J, Huang W, Dong J, Guo J, KP U et al (2020) CFTR promotes malignant glioma development via up-regulation of Akt\/Bcl2-mediated anti-apoptosis pathway. J Cell Mol Med 24(13):7301\u201312. https:\/\/doi.org\/10.1111\/jcmm.15300","journal-title":"J Cell Mol Med"},{"issue":"52","key":"4539_CR57","doi-asserted-by":"publisher","first-page":"89631","DOI":"10.18632\/oncotarget.20099","volume":"8","author":"WJ Zhu","year":"2017","unstructured":"Zhu WJ, Chen X, Wang YW, Liu HT, Ma RR, Gao P (2017) Mir-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway. Oncotarget 8(52):89631\u201389642. https:\/\/doi.org\/10.18632\/oncotarget.20099","journal-title":"Oncotarget"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04539-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:58:41Z","timestamp":1772006321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04539-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4539"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04539-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this experiment was obtained from the Experimental Animal Ethics Committee of Xinxiang Central Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The manuscript has neither been previously published nor is under consideration by any other journal. The authors have all approved the content of the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}